Clinical Trial Update: Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tislelizumab plus chemotherapy versus chemotherapy alone in recurrent or metastatic Nasopharyngeal cancer has completed and posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Recurrent or Metastatic Nasopharyngeal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2025-01-31